Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
NCT02952729
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
120
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Breast Cancer
Advanced Nonsmall Cell Lung Cancer
Advanced Gastric Cancer
Interventions
DRUG:
XMT-1522
Sponsor
Mersana Therapeutics